Therapeutic Goods Administration (TGA), November 12, 2025 – The International Medical Device Regulators Forum (IMDRF) has released a pivotal draft guidance titled “Essential Principles and Content of Predetermined Change Control Plans (PCCPs)”, marking a significant development in how software-based medical devices (SaMD) will be regulated across global jurisdictions.This draft, now open for public consultation until December 8, 2025, is designed to modernize regulatory processes and keep pace with the rapid iteration cycles of software development, especially in areas such as artificial intelligence (AI) and machine learning (ML) in healthcare.
WHAT ARE PCCPS AND WHY DO THEY MATTER?
Predetermined Change Control Plans (PCCPs) are forward-looking regulatory mechanisms that allow manufacturers to:
- Predefine a set of software changes at the time of initial approval.
- Avoid repetitive regulatory submissions for each software update, provided changes fall within the pre-approved scope.
- Enable faster deployment of improvements in clinical performance, usability, or cybersecurity.
The PCCP model acknowledges the agile nature of software updates and supports better alignment between development cycles and regulatory expectations.
KEY HIGHLIGHTS FROM THE IMDRF PUBLIC CONSULTATION DRAFT
- The draft outlines a broad yet harmonised framework that regulators can tailor to their local contexts.
- It provides essential principles and content expectations to guide manufacturers in drafting PCCPs as part of regulatory submissions.
- This harmonised approach is meant to encourage international consistency while offering flexibility to meet local regulatory requirements.
Stakeholders including manufacturers, software developers, regulatory consultants, and healthcare providers are encouraged to review the draft and offer feedback through the IMDRF Consultation Hub.
HOW DOES THIS IMPACT MANUFACTURERS?
1. Supports Faster Innovation
Manufacturers can release pre-approved software updates without undergoing full review, accelerating time to market and responsiveness to clinical needs.
2. Clarifies Regulatory Expectations
The framework provides clear guidelines on how to structure and justify PCCPs, helping companies streamline regulatory submissions.
3. Harmonised Global Approach
For manufacturers operating in multiple countries, this draft serves as a foundation for unified regulatory strategy, reducing duplicated efforts and enabling scalability.
4. Opportunity to Influence Final Guidance
By participating in the consultation, manufacturers have a chance to shape the global regulatory future of software-based medical devices.
WHAT SHOULD YOU DO NEXT?
- Download and review the PCCP draft available via the IMDRF website.
- Collaborate with internal regulatory and software teams to evaluate your current change management practices.
- Prepare structured feedback highlighting your views on feasibility, clarity, and operational impact.
- Submit your comments before the deadline on December 8, 2025.
FINAL SUMMARY
This consultation marks a progressive shift in regulatory science balancing safety and innovation. As the digital transformation of healthcare accelerates, frameworks like PCCPs ensure that regulatory agility keeps pace with software evolution. Manufacturers should not miss this opportunity to engage in the discussion and prepare for a regulatory environment that welcomes predictable and well-managed change.